




Curriculum Vitae

Personal Information	
Title	Prof.
Name	Chang Hwan CHOI
Degree	MD, PhD
Country	Korea
Affiliation	Chung-Ang University College of Medicine
E-mail	gicch(at)cau.ac.kr
	
Educational Background	
<p>- Sep. 2001 ~ Aug. 2004 Yonsei University College of Medicine Doctorate Course: Graduated Major: Gastroenterology</p> <p>- Mar. 1999 ~ Feb. 2001 Yonsei University College of Medicine Master's Course: Graduated Major: Internal medicine</p> <p>- Mar. 1991~ Feb. 1997 Yonsei University College of Medicine: Graduated</p>	
Professional Career	
<p>- Mar. 2015 ~ present Professor in Gastroenterology, Internal Medicine (Subspeciality: lower gastrointestinal diseases): Chung-Ang University College of Medicine</p> <p>- July 2013 ~ June 2014 Visiting Scholar in Gastroenterology, University of North Carolina, School of Medicine at Chapel Hill</p> <p>- Mar. 2010 ~ Feb. 2015 Associate Professor in Gastroenterology (Subspeciality: lower gastrointestinal diseases): Chung-Ang University College of Medicine</p> <p>- Mar. 2006 ~ Feb. 2010 Assistant Professor in Gastroenterology (Subspeciality: lower gastrointestinal diseases): Chung-Ang University College of Medicine</p> <p>- Mar. 2004 ~ Feb. 2006 Assistant Professor in Gastroenterology (Subspeciality: lower gastrointestinal diseases): Kwandong University College of Medicine</p> <p>- Mar. 2002 ~ Feb. 2004 Clinical Fellowship (Subspeciality: Gastroenterology) Division of Gastroenterology, Department of Internal Medicine, Yonsei University Severance Hospital in Seoul, South Korea Subspeciality board for Gastroenterology Acquired</p> <p>- Mar. 1997 ~ Feb. 2002 Yonsei University Severance Hospital, Dept. of Internal Medicine: Intern and Resident Course Medical Specialist in Internal Medicine Acquired</p>	

Research Field

Inflammatory bowel disease, Irritable bowel syndrome, Gut microbiota

Main Scientific Publications

- Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis. *Therap Adv Gastroenterol.* 2023 May 2;16:17562848231168199.
- Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. *Therap Adv Gastroenterol.* 2023 Mar 18;16:17562848231154103.
- Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease. *Intest Res.* 2023 Jan;21(1):148-160.
- Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. *Intest Res.* 2023 Jan;21(1):61-87.
- Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial. *J Neurogastroenterol Motil.* 2022 Oct 30;28(4):642-654.
- Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study. *Gut Liver.* 2022 Sep 15;16(5):764-774.
- Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study. *Intest Res.* 2022 Jul;20(3):350-360.